Singapore markets closed
Straits Times Index
3,367.90 +29.33 (+0.88%) S&P 500
5,470.98 -4.11 (-0.08%) Dow
39,114.05 -55.47 (-0.14%) Nasdaq
17,880.49 +1.19 (+0.01%) Bitcoin USD
62,684.45 +188.94 (+0.30%) CMC Crypto 200
1,342.29 -2.21 (-0.16%)
Bristol-Myers Squibb Co (BRM.HA)
Hanover - Hanover Delayed price. Currency in EUR
Add to watchlist
As of 08:04AM CEST. Market open.
| Previous close | 38.80 |
| Open | 38.34 |
| Bid | 38.33 x 0 |
| Ask | 38.53 x 0 |
| Day's range | 38.34 - 38.34 |
| 52-week range | 37.11 - 59.00 |
| Volume | |
| Avg. volume | 19 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
PRINCETON, N.J., June 21, 2024--Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with...
- Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
PRINCETON, N.J., June 21, 2024--European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab
- Business Wire
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
PRINCETON, N.J., June 20, 2024--Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
© 2024 Yahoo. All rights reserved.